Tonix Pharmaceuticals Secures $34M DOD Contract, Collaborates with X-Chem on Antiviral Research to Boost Development of Oral Antivirals Using AI and ML
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has secured a $34 million contract from the U.S. Department of Defense to advance its TNX-4200 antiviral program. The company is collaborating with X-Chem to use AI and ML in developing oral antivirals. This partnership aims to optimize drug candidates' properties and accelerate development.
October 08, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals has secured a $34 million contract from the U.S. Department of Defense to advance its TNX-4200 antiviral program. The collaboration with X-Chem aims to leverage AI and ML to optimize drug candidates, potentially accelerating development and enhancing the company's pipeline.
The $34M DOD contract provides significant funding to advance Tonix's TNX-4200 program, which is crucial for the company's development pipeline. The collaboration with X-Chem using AI/ML could enhance drug optimization, potentially leading to successful clinical outcomes. This news is likely to positively impact TNXP's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100